Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach
Executive Summary
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.
You may also be interested in...
Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
MorphoSys Targets 2020 Tafasitamab Launch Following Good DLBCL Data
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.
Probiodrug CEO Outlines Phase IIb Plans For Potential Alzheimer’s Treatments
Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.